Clinical Trial TitleA randomized phase 3 study of brentuximab vedotin (SGN-35, IND #117117) for newly diagnosed high-risk classical Hodgkin lymphoma (cHL) in children and young adults.
Clinical Trial Protocol Description:
Response directed therapy in high risk pediatric Hodgkin lymphoma with brentuximab added to standard therapy.
Clinical Trial Eligibility Criteria:
In order to participate you must meet the following criteria:
- Are between 2 and 22 years of age at the time of enrollment.
- Have newly diagnosed, pathologically confirmed cHL meeting one of the following Ann Arbor stages:
- Stage IIB with bulk
- Stage IIIB
- Stage IVA
- Stage IVB
This is a partial list of elgibility requirements.